IHIF Supports HB 1315 on biosimilar substitution

The Indiana Health Industry Forum has come out in support of Indiana HB 1315, which proposes legislation around the practice of substituting biosimilar therapies for their biologic counterparts.   Based on Five Principles for Biosimilar Substitution issued by the Biotechnology Industry Organization (BIO) and backed by the Pharmaceutical Research and Manufacturers Association (PhRMA), Indiana’s legislation echoes that already approved by several other states.

The House Committee on Public Health will be hold a hearing on the bill on January 23rd at 3:30 pm, Indiana statehouse room 156-C.

For more on BIO’s statement of support for HB 1315 and the principles of substitution, please visit the policy page on IHIF’s website. To track HB 1315, please click here


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: